Epitranscriptomics Market Likely to Surpass USD 3 Billion by 2035

Buy Now

A significant study discovering the market avenues on, “Epitranscriptomics Market Size, Share & Trends Analysis Report by Modification Type (m6A (N6-methyladenosine), m5C (5-methylcytosine), Pseudouridine (Ψ), m1A (N1-methyladenosine), m7G (7-methylguanosine), A-to-I Editing, Other Modifications), Technology/Method, Product Type, Application, Disease Area, End-Use Industry, Workflow Stage, Distribution Channel, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A holistic view of the market pathways in the epitranscriptomics market underscores revenue acceleration through three key levers scalable product line extensions, high‑maturity strategic partnerships

Global Epitranscriptomics Market Forecast 2035:

According to the report, the global epitranscriptomics market is projected to expand from USD 0.8 billion in 2025 to USD 3.0 billion by 2035, registering a CAGR of 14.3%, the highest during the forecast period. The epitranscriptomics market is experiencing a fast growth across the world where RNA modification is becoming one of the most important regulators of gene expression, cellular functions and the pathogenesis of diseases. This new science is leading to breakthroughs in precision medicine, which makes it possible to design targeted treatment to cancer, neurological diseases, metabolic diseases, and rare genetic diseases. The m6A sequencing, RNA methylation profiling, and single-cell epitranscriptomics technologies are driving the basic research and clinical use, providing scientists with the opportunity to discover novel biomarkers and therapeutic targets.

Epitranscriptomics is receiving huge investments in major research institutions, pharmaceutical companies, and biotech startups aiming to discover it faster with the use of next-generation sequencing, mass spectrometry, and advanced bioinformatics. North America has taken center stage with its well-developed research base, capital and biotech ecosystem whereas Asia-Pacific is up-and-coming with the government investment, increased research potential and entrepreneurial innovation. Technological advances, enhancement of translational research, and growth in the use of individualized medicine methods have contributed to the growth of the market and made epitranscriptomics an essential part of next-generation therapeutics and diagnostics in the world.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Epitranscriptomics Market”

The rising interest in personalized and precision medicine is a key catalyst of the epitranscriptomics market. Knowledge of RNA modifications can enable scientists and pharmaceutical firms to create targeted treatments to cancer, neurological diseases, metabolic diseases, and rare hereditary diseases. State-of-the-art technologies like m6A sequencing, RNA methylation profiling, and single-cell epitranscriptomics make it possible to identify new biomarkers more quickly in the development of therapies and enhance patient outcomes.

The epi-transcriptomics is the study of various types of RNA modification that have different chemical properties and biological functions, and it is inherently complex to analyze them. Sample preparation, detection and bioinformatic pipelines may vary resulting in laboratories having different results. The absence of generally accepted protocols and reference standards reduces reproducibility and extensive clinical implementation, making it difficult to translate research findings into effective diagnostics and therapeutic strategies.

Artificial intelligence and machine learning, combined with advanced bioinformatics tools, and next-generation sequencing are all opening up important possibilities in epitranscriptomics. These technologies can greatly enhance biomarker discovery and discovery of therapeutic targets by making the process of RNA modifications much faster and more precise. This integration will increase the rate at which drugs are developed, the mapping of diseases, and the application of personalized medicine, which has significant growth opportunities in the market by improving predictive modeling and simplifying the process of interpreting data.

Expansion of Global Epitranscriptomics Market

“Innovation, and public funding propel the global epitranscriptomics market expansion”

The epitranscriptomics market is experiencing an impressive growth in the global market that is largely due to the unceasing innovations in the RNA sequencing technologies, single-cell analysis and high-throughput detection mechanism. These developments are allowing further understanding of RNA modifications, new biomarkers, and the creation of targeted treatment. An example of this is the STORM Therapeutics that administered the first patient in a clinical partnership investigating STC-15, an RNA modification inhibitor that targets METTL3, with LOQTORZI. The objective of the study is to determine safety and optimum dose/synergy of treatment with cancers like NSCLC and melanoma, and emphasize the therapeutic advantages of regulating RNA alterations to enhance treatment results.
The adoption of epitranscriptomics can be significantly stimulated through government and insurance incentives to lower the financial cost of research and clinical adoption, to facilitate the implementation of precision medicine efforts, and to increase the speed of the development and availability of RNA alteration-based diagnostics and therapies. Legal decisions like encouraging funding, reimbursement and ease of regulation access has emboldened academic institutions and biotech firms to invest in epitranscriptomic technologies and ultimately bring them into mainstream healthcare and translational research systems worldwide. As an example, the U.S. National Institutes of Health (NIH) and National Science Foundation (NSF) in 2024 declared a collaborative investment of 15.4 million dollars in RNA research, such as research into RNA modifications. This funding helps to advance technologies to learn more about RNA biology and its use in health and disease, and drive innovation in the field of epitranscriptomics.

Regional Analysis of Global Epitranscriptomics Market

The most promising market is the epitranscriptomics market in North America because of the well-established research infrastructure, the concentration of the major biotech and pharmaceutical companies, and the large amount of government and private funds dedicated to the research of RNA modification. The area is swiftly implementing modern technologies, including single-cell epitranscriptomics, high-throughput RNA sequencing, and AI-enhanced bioinformatics, which can be utilized to discover biomarkers and develop therapies more quickly. All these contribute to the advantages of translational research and development of RNA modification-based diagnostics and therapeutics, making North America a world leader in epitranscriptomics.
The Asia-Pacific market is projected to experience the greatest growth due to the increased government investments in biotechnology and RNA modification studies of countries like China, Japan, South Korea and India. The region has a rising number of academic and private research institutions, fast uptake of the latest sequencing technology, and a booming biotech startup ecosystem. An increased need of precision medicine and novel therapeutics is spurring the growth and clinical implementation of epitranscriptomic diagnostics and therapies.

Prominent players operating in the global epitranscriptomics market are Abcam, Active Motif, Agilent Technologies, Arraystar, Bio-Rad Laboratories, CD Genomics, Cell Signaling Technology, Creative Biolabs, EpiGentek, Epigentek Group, Genecopoeia, Illumina, LC Sciences, Merck KGaA, Moderna, Inc., New England Biolabs (NEB), Oxford Nanopore Technologies, Pacific Biosciences (PacBio), PerkinElmer, QIAGEN, Takara Bio, Thermo Fisher Scientific, Zymo Research, and Other Key Players.

The global Epitranscriptomics market has been segmented as follows:

Global Epitranscriptomics Market Analysis, By Modification Type

m6A (N6-methyladenosine)
- Writers (METTL3, METTL14)
- Erasers (FTO, ALKBH5)
- Readers (YTHDF proteins)
- Others
m5C (5-methylcytosine)
Pseudouridine (Ψ)
m1A (N1-methyladenosine)
m7G (7-methylguanosine)
A-to-I Editing
Other Modifications

Global Epitranscriptomics Market Analysis, By Technology/Method

Sequencing-Based Methods
- MeRIP-seq/m6A-seq
- miCLIP
- PA-m6A-seq
- DART-seq
- Others
Mass Spectrometry
- LC-MS/MS
- UHPLC-MS/MS
- Others
Antibody-Based Detection
Chemical Labeling Methods
Nanopore Sequencing
Enzymatic Methods
Others

Global Epitranscriptomics Market Analysis, By Product Type

Kits & Reagents
- RNA modification detection kits
- Enrichment kits
- Sequencing library preparation kits
- Others
Instruments & Equipment
Software & Bioinformatics Tools
Services

Global Epitranscriptomics Market Analysis, By RNA Type

mRNA (Messenger RNA)
tRNA (Transfer RNA)
rRNA (Ribosomal RNA)
lncRNA (Long Non-coding RNA)
miRNA (MicroRNA)
circRNA (Circular RNA)
snRNA (Small Nuclear RNA)
Others

Global Epitranscriptomics Market Analysis, By Application

Disease Biomarker Discovery
Drug Target Identification
Therapeutics Development
- mRNA therapeutics
- Antisense oligonucleotides
- Small molecule modulators
- Others
Basic Research
Diagnostic Development
Personalized Medicine
Vaccine Development
Others

Global Epitranscriptomics Market Analysis, By Disease Area

Cancer/Oncology
- Leukemia
- Breast cancer
- Lung cancer
- Liver cancer
- Others
Neurological Disorders
- Alzheimer's disease
- Parkinson's disease
- Glioblastoma
- Others
Metabolic Disorders
- Obesity
- Diabetes
- Others
Cardiovascular Diseases
Infectious Diseases
Immunological Disorders
Others

Global Epitranscriptomics Market Analysis, By End-Use Industry

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations (CROs)
Diagnostic Laboratories
Hospital & Clinical Laboratories
Others

Global Epitranscriptomics Market Analysis, By Workflow Stage

Sample Preparation
RNA Extraction & Purification
Modification Detection
Enrichment & Immunoprecipitation
Sequencing & Analysis
Data Interpretation

Global Epitranscriptomics Market Analysis, by Distribution Channel

Direct Sales
Distributors & Resellers
Online Channels

Global Epitranscriptomics Market Analysis, By Region

North America
Europe
Asia Pacific
Middle East
Africa
South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
  - 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
  - 1.6.1. Open Sources
  - 1.6.2. Paid Databases
  - 1.6.3. Associations
- 1.7. Primary Research
  - 1.7.1. Primary Sources
  - 1.7.2. Primary Interviews with Stakeholders across Ecosystem
2. Executive Summary
- 2.1. Global Epitranscriptomics Market Outlook
  - 2.1.1. Epitranscriptomics Market Size (Value - US$ Bn), and Forecasts, 2021-2035
  - 2.1.2. Compounded Annual Growth Rate Analysis
  - 2.1.3. Growth Opportunity Analysis
  - 2.1.4. Segmental Share Analysis
  - 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
  - 2.5.1. Customer/ End-use Industry Assessment
  - 2.5.2. Growth Opportunity Data, 2025-2035
    - 2.5.2.1. Regional Data
    - 2.5.2.2. Country Data
    - 2.5.2.3. Segmental Data
  - 2.5.3. Identification of Potential Market Spaces
  - 2.5.4. GAP Analysis
  - 2.5.5. Potential Attractive Price Points
  - 2.5.6. Prevailing Market Risks & Challenges
  - 2.5.7. Preferred Sales & Marketing Strategies
  - 2.5.8. Key Recommendations and Analysis
  - 2.5.9. A Way Forward
3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
  - 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
  - 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
  - 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.4. Trade Analysis
  - 3.4.1. Import & Export Analysis, 2025
  - 3.4.2. Top Importing Countries
  - 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
  - 3.5.1. Manufacturer
    - 3.5.1.1. Based on the component & Raw material
  - 3.5.2. Supply Chain
  - 3.5.3. End Consumer
- 3.6. Raw Material Analysis
4. Market Overview
- 4.1. Market Dynamics
  - 4.1.1. Drivers
    - 4.1.1.1. Rising demand for RNA modification-based biomarkers in precision medicine
    - 4.1.1.2. Advancements in sequencing technologies enabling single-cell epitranscriptomic profiling
    - 4.1.1.3. Expanding academic–industry collaborations for RNA-targeted drug discovery
  - 4.1.2. Restraints
    - 4.1.2.1. High cost and complexity of epitranscriptomic data analysis
    - 4.1.2.2. Limited standardization and reproducibility across detection platforms
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
  - 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
  - 4.3.2. Tariffs and Standards
  - 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
  - 4.4.1. Raw Materials & Reagents Suppliers
  - 4.4.2. Product Development & Manufacturing
  - 4.4.3. Distributors
  - 4.4.4. End-users/ Customers
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global Epitranscriptomics Market Demand
  - 4.7.1. Historical Market Size - in Value (US$ Bn), 2020-2024
  - 4.7.2. Current and Future Market Size - in Value (US$ Bn), 2025–2035
    - 4.7.2.1. Y-o-Y Growth Trends
    - 4.7.2.2. Absolute $ Opportunity Assessment
5. Competition Landscape
- 5.1. Competition structure
  - 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
  - 5.2.1. Global Company Market Share
  - 5.2.2. By Region
    - 5.2.2.1. North America
    - 5.2.2.2. Europe
    - 5.2.2.3. Asia Pacific
    - 5.2.2.4. Middle East
    - 5.2.2.5. Africa
    - 5.2.2.6. South America
- 5.3. Product Comparison Matrix
  - 5.3.1. Specifications
  - 5.3.2. Market Positioning
  - 5.3.3. Pricing
6. Global Epitranscriptomics Market Analysis, By Modification Type
- 6.1. Key Segment Analysis
- 6.2. Epitranscriptomics Market Size (Value - US$ Bn), Analysis, and Forecasts, By Modification Type, 2021-2035
  - 6.2.1. m6A (N6-methyladenosine)
    - 6.2.1.1. Writers (METTL3, METTL14)
    - 6.2.1.2. Erasers (FTO, ALKBH5)
    - 6.2.1.3. Readers (YTHDF proteins)
    - 6.2.1.4. Others
  - 6.2.2. m5C (5-methylcytosine)
  - 6.2.3. Pseudouridine (Ψ)
  - 6.2.4. m1A (N1-methyladenosine)
  - 6.2.5. m7G (7-methylguanosine)
  - 6.2.6. A-to-I Editing
  - 6.2.7. Other Modifications
7. Global Epitranscriptomics Market Analysis, By Technology/Method
- 7.1. Key Segment Analysis
- 7.2. Epitranscriptomics Market Size (Value - US$ Bn), Analysis, and Forecasts, By Technology/Method, 2021-2035
  - 7.2.1. Sequencing-Based Methods
    - 7.2.1.1. MeRIP-seq/m6A-seq
    - 7.2.1.2. miCLIP
    - 7.2.1.3. PA-m6A-seq
    - 7.2.1.4. DART-seq
    - 7.2.1.5. Others
  - 7.2.2. Mass Spectrometry
    - 7.2.2.1. LC-MS/MS
    - 7.2.2.2. UHPLC-MS/MS
    - 7.2.2.3. Others
  - 7.2.3. Antibody-Based Detection
  - 7.2.4. Chemical Labeling Methods
  - 7.2.5. Nanopore Sequencing
  - 7.2.6. Enzymatic Methods
  - 7.2.7. Others
8. Global Epitranscriptomics Market Analysis and Forecasts,By Product Type
- 8.1. Key Findings
- 8.2. Epitranscriptomics Market Size (Value - US$ Mn), Analysis, and Forecasts, By Product Type, 2021-2035
  - 8.2.1. Kits & Reagents
    - 8.2.1.1. RNA modification detection kits
    - 8.2.1.2. Enrichment kits
    - 8.2.1.3. Sequencing library preparation kits
    - 8.2.1.4. Others
  - 8.2.2. Instruments & Equipment
  - 8.2.3. Software & Bioinformatics Tools
  - 8.2.4. Services
9. Global Epitranscriptomics Market Analysis and Forecasts, By RNA Type
- 9.1. Key Findings
- 9.2. Epitranscriptomics Market Size (Vo Value - US$ Mn), Analysis, and Forecasts, By RNA Type, 2021-2035
  - 9.2.1. mRNA (Messenger RNA)
  - 9.2.2. tRNA (Transfer RNA)
  - 9.2.3. rRNA (Ribosomal RNA)
  - 9.2.4. lncRNA (Long Non-coding RNA)
  - 9.2.5. miRNA (MicroRNA)
  - 9.2.6. circRNA (Circular RNA)
  - 9.2.7. snRNA (Small Nuclear RNA)
  - 9.2.8. Others
10. Global Epitranscriptomics Market Analysis and Forecasts, By Application
- 10.1. Key Findings
- 10.2. Epitranscriptomics Market Size (Value - US$ Mn), Analysis, and Forecasts, By Application, 2021-2035
  - 10.2.1. Disease Biomarker Discovery
  - 10.2.2. Drug Target Identification
  - 10.2.3. Therapeutics Development
    - 10.2.3.1. mRNA therapeutics
    - 10.2.3.2. Antisense oligonucleotides
    - 10.2.3.3. Small molecule modulators
    - 10.2.3.4. Others
  - 10.2.4. Basic Research
  - 10.2.5. Diagnostic Development
  - 10.2.6. Personalized Medicine
  - 10.2.7. Vaccine Development
  - 10.2.8. Others
11. Global Epitranscriptomics Market Analysis and Forecasts, By Disease Area
- 11.1. Key Findings
- 11.2. Epitranscriptomics Market Size (Value - US$ Mn), Analysis, and Forecasts, By Disease Area, 2021-2035
  - 11.2.1. Cancer/Oncology
    - 11.2.1.1. Leukemia
    - 11.2.1.2. Breast cancer
    - 11.2.1.3. Lung cancer
    - 11.2.1.4. Liver cancer
    - 11.2.1.5. Others
  - 11.2.2. Neurological Disorders
    - 11.2.2.1. Alzheimer's disease
    - 11.2.2.2. Parkinson's disease
    - 11.2.2.3. Glioblastoma
    - 11.2.2.4. Others
  - 11.2.3. Metabolic Disorders
    - 11.2.3.1. Obesity
    - 11.2.3.2. Diabetes
    - 11.2.3.3. Others
  - 11.2.4. Cardiovascular Diseases
  - 11.2.5. Infectious Diseases
  - 11.2.6. Immunological Disorders
  - 11.2.7. Others
12. Global Epitranscriptomics Market Analysis and Forecasts, By End-Use Industry
- 12.1. Key Findings
- 12.2. Epitranscriptomics Market Size (Value - US$ Mn), Analysis, and Forecasts, By Delivery Mode, 2021-2035
  - 12.2.1. Pharmaceutical & Biotechnology Companies
  - 12.2.2. Academic & Research Institutes
  - 12.2.3. Contract Research Organizations (CROs)
  - 12.2.4. Diagnostic Laboratories
  - 12.2.5. Hospital & Clinical Laboratories
  - 12.2.6. Others
13. Global Epitranscriptomics Market Analysis and Forecasts, By Workflow Stage
- 13.1. Key Findings
- 13.2. Epitranscriptomics Market Size (Value - US$ Mn), Analysis, and Forecasts, By Workflow Stage, 2021-2035
  - 13.2.1. Sample Preparation
  - 13.2.2. RNA Extraction & Purification
  - 13.2.3. Modification Detection
  - 13.2.4. Enrichment & Immunoprecipitation
  - 13.2.5. Sequencing & Analysis
  - 13.2.6. Data Interpretation
14. Global Epitranscriptomics Market Analysis and Forecasts, By Distribution Channel
- 14.1. Key Findings
- 14.2. Epitranscriptomics Market Size (Value - US$ Mn), Analysis, and Forecasts, By Distribution Channel, 2021-2035
  - 14.2.1. Direct Sales
  - 14.2.2. Distributors & Resellers
  - 14.2.3. Online Channels
15. Global Epitranscriptomics Market Analysis and Forecasts, by Region
- 15.1. Key Findings
- 15.2. Epitranscriptomics Market Size (Value - US$ Mn), Analysis, and Forecasts, by Region, 2021-2035
  - 15.2.1. North America
  - 15.2.2. Europe
  - 15.2.3. Asia Pacific
  - 15.2.4. Middle East
  - 15.2.5. Africa
  - 15.2.6. South America
16. North America Epitranscriptomics Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. North America Epitranscriptomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 16.3.1. Modification Type
  - 16.3.2. Technology/Method
  - 16.3.3. Product Type
  - 16.3.4. RNA Type
  - 16.3.5. Application
  - 16.3.6. Disease Area
  - 16.3.7. End-Use Industry
  - 16.3.8. Workflow Stage
  - 16.3.9. Distribution Channel
  - 16.3.10. Country
    - 16.3.10.1. USA
    - 16.3.10.2. Canada
    - 16.3.10.3. Mexico
- 16.4. USA Epitranscriptomics Market
  - 16.4.1. Country Segmental Analysis
  - 16.4.2. Modification Type
  - 16.4.3. Technology/Method
  - 16.4.4. Product Type
  - 16.4.5. RNA Type
  - 16.4.6. Application
  - 16.4.7. Disease Area
  - 16.4.8. End-Use Industry
  - 16.4.9. Workflow Stage
  - 16.4.10. Distribution Channel
- 16.5. Canada Epitranscriptomics Market
  - 16.5.1. Country Segmental Analysis
  - 16.5.2. Modification Type
  - 16.5.3. Technology/Method
  - 16.5.4. Product Type
  - 16.5.5. RNA Type
  - 16.5.6. Application
  - 16.5.7. Disease Area
  - 16.5.8. End-Use Industry
  - 16.5.9. Workflow Stage
  - 16.5.10. Distribution Channel
- 16.6. Mexico Epitranscriptomics Market
  - 16.6.1. Country Segmental Analysis
  - 16.6.2. Modification Type
  - 16.6.3. Technology/Method
  - 16.6.4. Product Type
  - 16.6.5. RNA Type
  - 16.6.6. Application
  - 16.6.7. Disease Area
  - 16.6.8. End-Use Industry
  - 16.6.9. Workflow Stage
  - 16.6.10. Distribution Channel
17. Europe Epitranscriptomics Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Europe Epitranscriptomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 17.3.1. Therapeutic Application
  - 17.3.2. Modification Type
  - 17.3.3. Technology/Method
  - 17.3.4. Product Type
  - 17.3.5. RNA Type
  - 17.3.6. Application
  - 17.3.7. Disease Area
  - 17.3.8. End-Use Industry
  - 17.3.9. Workflow Stage
  - 17.3.10. Distribution Channel
  - 17.3.11. Country
    - 17.3.11.1. Germany
    - 17.3.11.2. United Kingdom
    - 17.3.11.3. France
    - 17.3.11.4. Italy
    - 17.3.11.5. Spain
    - 17.3.11.6. Netherlands
    - 17.3.11.7. Nordic Countries
    - 17.3.11.8. Poland
    - 17.3.11.9. Russia & CIS
    - 17.3.11.10. Rest of Europe
- 17.4. Germany Epitranscriptomics Market
  - 17.4.1. Country Segmental Analysis
  - 17.4.2. Modification Type
  - 17.4.3. Technology/Method
  - 17.4.4. Product Type
  - 17.4.5. RNA Type
  - 17.4.6. Application
  - 17.4.7. Disease Area
  - 17.4.8. End-Use Industry
  - 17.4.9. Workflow Stage
  - 17.4.10. Distribution Channel
- 17.5. United Kingdom Epitranscriptomics Market
  - 17.5.1. Country Segmental Analysis
  - 17.5.2. Modification Type
  - 17.5.3. Technology/Method
  - 17.5.4. Product Type
  - 17.5.5. RNA Type
  - 17.5.6. Application
  - 17.5.7. Disease Area
  - 17.5.8. End-Use Industry
  - 17.5.9. Workflow Stage
  - 17.5.10. Distribution Channel
- 17.6. France Epitranscriptomics Market
  - 17.6.1. Country Segmental Analysis
  - 17.6.2. Modification Type
  - 17.6.3. Technology/Method
  - 17.6.4. Product Type
  - 17.6.5. RNA Type
  - 17.6.6. Application
  - 17.6.7. Disease Area
  - 17.6.8. End-Use Industry
  - 17.6.9. Workflow Stage
  - 17.6.10. Distribution Channel
- 17.7. Italy Epitranscriptomics Market
  - 17.7.1. Country Segmental Analysis
  - 17.7.2. Modification Type
  - 17.7.3. Technology/Method
  - 17.7.4. Product Type
  - 17.7.5. RNA Type
  - 17.7.6. Application
  - 17.7.7. Disease Area
  - 17.7.8. End-Use Industry
  - 17.7.9. Workflow Stage
  - 17.7.10. Distribution Channel
- 17.8. Spain Epitranscriptomics Market
  - 17.8.1. Therapeutic Application
  - 17.8.2. Modification Type
  - 17.8.3. Technology/Method
  - 17.8.4. Product Type
  - 17.8.5. RNA Type
  - 17.8.6. Application
  - 17.8.7. Disease Area
  - 17.8.8. End-Use Industry
  - 17.8.9. Workflow Stage
  - 17.8.10. Distribution Channel
- 17.9. Netherlands Epitranscriptomics Market
  - 17.9.1. Country Segmental Analysis
  - 17.9.2. Modification Type
  - 17.9.3. Technology/Method
  - 17.9.4. Product Type
  - 17.9.5. RNA Type
  - 17.9.6. Application
  - 17.9.7. Disease Area
  - 17.9.8. End-Use Industry
  - 17.9.9. Workflow Stage
  - 17.9.10. Distribution Channel
- 17.10. Nordic Countries Epitranscriptomics Market
  - 17.10.1. Country Segmental Analysis
  - 17.10.2. Modification Type
  - 17.10.3. Technology/Method
  - 17.10.4. Product Type
  - 17.10.5. RNA Type
  - 17.10.6. Application
  - 17.10.7. Disease Area
  - 17.10.8. End-Use Industry
  - 17.10.9. Workflow Stage
  - 17.10.10. Distribution Channel
- 17.11. Poland Epitranscriptomics Market
  - 17.11.1. Country Segmental Analysis
  - 17.11.2. Modification Type
  - 17.11.3. Technology/Method
  - 17.11.4. Product Type
  - 17.11.5. RNA Type
  - 17.11.6. Application
  - 17.11.7. Disease Area
  - 17.11.8. End-Use Industry
  - 17.11.9. Workflow Stage
  - 17.11.10. Distribution Channel
- 17.12. Russia & CIS Epitranscriptomics Market
  - 17.12.1. Country Segmental Analysis
  - 17.12.2. Modification Type
  - 17.12.3. Technology/Method
  - 17.12.4. Product Type
  - 17.12.5. RNA Type
  - 17.12.6. Application
  - 17.12.7. Disease Area
  - 17.12.8. End-Use Industry
  - 17.12.9. Workflow Stage
  - 17.12.10. Distribution Channel
- 17.13. Rest of Europe Epitranscriptomics Market
  - 17.13.1. Country Segmental Analysis
  - 17.13.2. Modification Type
  - 17.13.3. Technology/Method
  - 17.13.4. Product Type
  - 17.13.5. RNA Type
  - 17.13.6. Application
  - 17.13.7. Disease Area
  - 17.13.8. End-Use Industry
  - 17.13.9. Workflow Stage
  - 17.13.10. Distribution Channel
18. Asia Pacific Epitranscriptomics Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. East Asia Epitranscriptomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 18.3.1. Modification Type
  - 18.3.2. Technology/Method
  - 18.3.3. Product Type
  - 18.3.4. RNA Type
  - 18.3.5. Application
  - 18.3.6. Disease Area
  - 18.3.7. End-Use Industry
  - 18.3.8. Workflow Stage
  - 18.3.9. Distribution Channel
  - 18.3.10. Country
    - 18.3.10.1. China
    - 18.3.10.2. India
    - 18.3.10.3. Japan
    - 18.3.10.4. South Korea
    - 18.3.10.5. Australia and New Zealand
    - 18.3.10.6. Indonesia
    - 18.3.10.7. Malaysia
    - 18.3.10.8. Thailand
    - 18.3.10.9. Vietnam
    - 18.3.10.10. Rest of Asia Pacific
- 18.4. China Epitranscriptomics Market
  - 18.4.1. Country Segmental Analysis
  - 18.4.2. Modification Type
  - 18.4.3. Technology/Method
  - 18.4.4. Product Type
  - 18.4.5. RNA Type
  - 18.4.6. Application
  - 18.4.7. Disease Area
  - 18.4.8. End-Use Industry
  - 18.4.9. Workflow Stage
  - 18.4.10. Distribution Channel
- 18.5. India Epitranscriptomics Market
  - 18.5.1. Country Segmental Analysis
  - 18.5.2. Modification Type
  - 18.5.3. Technology/Method
  - 18.5.4. Product Type
  - 18.5.5. RNA Type
  - 18.5.6. Application
  - 18.5.7. Disease Area
  - 18.5.8. End-Use Industry
  - 18.5.9. Workflow Stage
  - 18.5.10. Distribution Channel
- 18.6. Japan Epitranscriptomics Market
  - 18.6.1. Country Segmental Analysis
  - 18.6.2. Modification Type
  - 18.6.3. Technology/Method
  - 18.6.4. Product Type
  - 18.6.5. RNA Type
  - 18.6.6. Application
  - 18.6.7. Disease Area
  - 18.6.8. End-Use Industry
  - 18.6.9. Workflow Stage
  - 18.6.10. Distribution Channel
- 18.7. South Korea Epitranscriptomics Market
  - 18.7.1. Country Segmental Analysis
  - 18.7.2. Modification Type
  - 18.7.3. Technology/Method
  - 18.7.4. Product Type
  - 18.7.5. RNA Type
  - 18.7.6. Application
  - 18.7.7. Disease Area
  - 18.7.8. End-Use Industry
  - 18.7.9. Workflow Stage
  - 18.7.10. Distribution Channel
- 18.8. Australia and New Zealand Epitranscriptomics Market
  - 18.8.1. Country Segmental Analysis
  - 18.8.2. Modification Type
  - 18.8.3. Technology/Method
  - 18.8.4. Product Type
  - 18.8.5. RNA Type
  - 18.8.6. Application
  - 18.8.7. Disease Area
  - 18.8.8. End-Use Industry
  - 18.8.9. Workflow Stage
  - 18.8.10. Distribution Channel
- 18.9. Indonesia Epitranscriptomics Market
  - 18.9.1. Country Segmental Analysis
  - 18.9.2. Modification Type
  - 18.9.3. Technology/Method
  - 18.9.4. Product Type
  - 18.9.5. RNA Type
  - 18.9.6. Application
  - 18.9.7. Disease Area
  - 18.9.8. End-Use Industry
  - 18.9.9. Workflow Stage
  - 18.9.10. Distribution Channel
- 18.10. Malaysia Epitranscriptomics Market
  - 18.10.1. Country Segmental Analysis
  - 18.10.2. Modification Type
  - 18.10.3. Technology/Method
  - 18.10.4. Product Type
  - 18.10.5. RNA Type
  - 18.10.6. Application
  - 18.10.7. Disease Area
  - 18.10.8. End-Use Industry
  - 18.10.9. Workflow Stage
  - 18.10.10. Distribution Channel
- 18.11. Thailand Epitranscriptomics Market
  - 18.11.1. Country Segmental Analysis
  - 18.11.2. Modification Type
  - 18.11.3. Technology/Method
  - 18.11.4. Product Type
  - 18.11.5. RNA Type
  - 18.11.6. Application
  - 18.11.7. Disease Area
  - 18.11.8. End-Use Industry
  - 18.11.9. Workflow Stage
  - 18.11.10. Distribution Channel
- 18.12. Vietnam Epitranscriptomics Market
  - 18.12.1. Country Segmental Analysis
  - 18.12.2. Modification Type
  - 18.12.3. Technology/Method
  - 18.12.4. Product Type
  - 18.12.5. RNA Type
  - 18.12.6. Application
  - 18.12.7. Disease Area
  - 18.12.8. End-Use Industry
  - 18.12.9. Workflow Stage
  - 18.12.10. Distribution Channel
- 18.13. Rest of Asia Pacific Epitranscriptomics Market
  - 18.13.1. Country Segmental Analysis
  - 18.13.2. Modification Type
  - 18.13.3. Technology/Method
  - 18.13.4. Product Type
  - 18.13.5. RNA Type
  - 18.13.6. Application
  - 18.13.7. Disease Area
  - 18.13.8. End-Use Industry
  - 18.13.9. Workflow Stage
  - 18.13.10. Distribution Channel
19. Middle East Epitranscriptomics Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Middle East Epitranscriptomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 19.3.1. Therapeutic Application
  - 19.3.2. Modification Type
  - 19.3.3. Technology/Method
  - 19.3.4. Product Type
  - 19.3.5. RNA Type
  - 19.3.6. Application
  - 19.3.7. Disease Area
  - 19.3.8. End-Use Industry
  - 19.3.9. Workflow Stage
  - 19.3.10. Distribution Channel
  - 19.3.11. Country
    - 19.3.11.1. Turkey
    - 19.3.11.2. UAE
    - 19.3.11.3. Saudi Arabia
    - 19.3.11.4. Israel
    - 19.3.11.5. Rest of Middle East
- 19.4. Turkey Epitranscriptomics Market
  - 19.4.1. Country Segmental Analysis
  - 19.4.2. Modification Type
  - 19.4.3. Technology/Method
  - 19.4.4. Product Type
  - 19.4.5. RNA Type
  - 19.4.6. Application
  - 19.4.7. Disease Area
  - 19.4.8. End-Use Industry
  - 19.4.9. Workflow Stage
  - 19.4.10. Distribution Channel
- 19.5. UAE Epitranscriptomics Market
  - 19.5.1. Country Segmental Analysis
  - 19.5.2. Modification Type
  - 19.5.3. Technology/Method
  - 19.5.4. Product Type
  - 19.5.5. RNA Type
  - 19.5.6. Application
  - 19.5.7. Disease Area
  - 19.5.8. End-Use Industry
  - 19.5.9. Workflow Stage
  - 19.5.10. Distribution Channel
- 19.6. Saudi Arabia Epitranscriptomics Market
  - 19.6.1. Country Segmental Analysis
  - 19.6.2. Modification Type
  - 19.6.3. Technology/Method
  - 19.6.4. Product Type
  - 19.6.5. RNA Type
  - 19.6.6. Application
  - 19.6.7. Disease Area
  - 19.6.8. End-Use Industry
  - 19.6.9. Workflow Stage
  - 19.6.10. Distribution Channel
- 19.7. Israel Epitranscriptomics Market
  - 19.7.1. Country Segmental Analysis
  - 19.7.2. Modification Type
  - 19.7.3. Technology/Method
  - 19.7.4. Product Type
  - 19.7.5. RNA Type
  - 19.7.6. Application
  - 19.7.7. Disease Area
  - 19.7.8. End-Use Industry
  - 19.7.9. Workflow Stage
  - 19.7.10. Distribution Channel
- 19.8. Rest of Middle East Epitranscriptomics Market
  - 19.8.1. Country Segmental Analysis
  - 19.8.2. Modification Type
  - 19.8.3. Technology/Method
  - 19.8.4. Product Type
  - 19.8.5. RNA Type
  - 19.8.6. Application
  - 19.8.7. Disease Area
  - 19.8.8. End-Use Industry
  - 19.8.9. Workflow Stage
  - 19.8.10. Distribution Channel
20. Africa Epitranscriptomics Market Analysis
- 20.1. Key Segment Analysis
- 20.2. Regional Snapshot
- 20.3. Africa Epitranscriptomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 20.3.1. Therapeutic Application
  - 20.3.2. Modification Type
  - 20.3.3. Technology/Method
  - 20.3.4. Product Type
  - 20.3.5. RNA Type
  - 20.3.6. Application
  - 20.3.7. Disease Area
  - 20.3.8. End-Use Industry
  - 20.3.9. Workflow Stage
  - 20.3.10. Distribution Channel
  - 20.3.11. Country
    - 20.3.11.1. South Africa
    - 20.3.11.2. Egypt
    - 20.3.11.3. Nigeria
    - 20.3.11.4. Algeria
    - 20.3.11.5. Rest of Africa
- 20.4. South Africa Epitranscriptomics Market
  - 20.4.1. Country Segmental Analysis
  - 20.4.2. Modification Type
  - 20.4.3. Technology/Method
  - 20.4.4. Product Type
  - 20.4.5. RNA Type
  - 20.4.6. Application
  - 20.4.7. Disease Area
  - 20.4.8. End-Use Industry
  - 20.4.9. Workflow Stage
  - 20.4.10. Distribution Channel
- 20.5. Egypt Epitranscriptomics Market
  - 20.5.1. Country Segmental Analysis
  - 20.5.2. Modification Type
  - 20.5.3. Technology/Method
  - 20.5.4. Product Type
  - 20.5.5. RNA Type
  - 20.5.6. Application
  - 20.5.7. Disease Area
  - 20.5.8. End-Use Industry
  - 20.5.9. Workflow Stage
  - 20.5.10. Distribution Channel
- 20.6. Nigeria Epitranscriptomics Market
  - 20.6.1. Country Segmental Analysis
  - 20.6.2. Modification Type
  - 20.6.3. Technology/Method
  - 20.6.4. Product Type
  - 20.6.5. RNA Type
  - 20.6.6. Application
  - 20.6.7. Disease Area
  - 20.6.8. End-Use Industry
  - 20.6.9. Workflow Stage
  - 20.6.10. Distribution Channel
- 20.7. Algeria Epitranscriptomics Market
  - 20.7.1. Country Segmental Analysis
  - 20.7.2. Modification Type
  - 20.7.3. Technology/Method
  - 20.7.4. Product Type
  - 20.7.5. RNA Type
  - 20.7.6. Application
  - 20.7.7. Disease Area
  - 20.7.8. End-Use Industry
  - 20.7.9. Workflow Stage
  - 20.7.10. Distribution Channel
- 20.8. Rest of Africa Epitranscriptomics Market
  - 20.8.1. Country Segmental Analysis
  - 20.8.2. Modification Type
  - 20.8.3. Technology/Method
  - 20.8.4. Product Type
  - 20.8.5. RNA Type
  - 20.8.6. Application
  - 20.8.7. Disease Area
  - 20.8.8. End-Use Industry
  - 20.8.9. Workflow Stage
  - 20.8.10. Distribution Channel
21. South America Epitranscriptomics Market Analysis
- 21.1. Key Segment Analysis
- 21.2. Regional Snapshot
- 21.3. Central and South Africa Epitranscriptomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 21.3.1. Therapeutic Application
  - 21.3.2. Modification Type
  - 21.3.3. Technology/Method
  - 21.3.4. Product Type
  - 21.3.5. RNA Type
  - 21.3.6. Application
  - 21.3.7. Disease Area
  - 21.3.8. End-Use Industry
  - 21.3.9. Workflow Stage
  - 21.3.10. Distribution Channel
  - 21.3.11. Country
    - 21.3.11.1. Brazil
    - 21.3.11.2. Argentina
    - 21.3.11.3. Rest of South America
- 21.4. Brazil Epitranscriptomics Market
  - 21.4.1. Country Segmental Analysis
  - 21.4.2. Modification Type
  - 21.4.3. Technology/Method
  - 21.4.4. Product Type
  - 21.4.5. RNA Type
  - 21.4.6. Application
  - 21.4.7. Disease Area
  - 21.4.8. End-Use Industry
  - 21.4.9. Workflow Stage
  - 21.4.10. Distribution Channel
- 21.5. Argentina Epitranscriptomics Market
  - 21.5.1. Country Segmental Analysis
  - 21.5.2. Modification Type
  - 21.5.3. Technology/Method
  - 21.5.4. Product Type
  - 21.5.5. RNA Type
  - 21.5.6. Application
  - 21.5.7. Disease Area
  - 21.5.8. End-Use Industry
  - 21.5.9. Workflow Stage
  - 21.5.10. Distribution Channel
- 21.6. Rest of South America Epitranscriptomics Market
  - 21.6.1. Country Segmental Analysis
  - 21.6.2. Modification Type
  - 21.6.3. Technology/Method
  - 21.6.4. Product Type
  - 21.6.5. RNA Type
  - 21.6.6. Application
  - 21.6.7. Disease Area
  - 21.6.8. End-Use Industry
  - 21.6.9. Workflow Stage
  - 21.6.10. Distribution Channel
22. Key Players/ Company Profile
- 22.1. Abcam
  - 22.1.1. Company Details/ Overview
  - 22.1.2. Company Financials
  - 22.1.3. Key Customers and Competitors
  - 22.1.4. Business/ Industry Portfolio
  - 22.1.5. Product Portfolio/ Specification Details
  - 22.1.6. Pricing Data
  - 22.1.7. Strategic Overview
  - 22.1.8. Recent Developments
- 22.2. Active Motif
- 22.3. Agilent Technologies
- 22.4. Arraystar
- 22.5. Bio-Rad Laboratories
- 22.6. CD Genomics
- 22.7. Cell Signaling Technology
- 22.8. Creative Biolabs
- 22.9. EpiGentek
- 22.10. Epigentek Group
- 22.11. Genecopoeia
- 22.12. Illumina
- 22.13. LC Sciences
- 22.14. Merck KGaA
- 22.15. Moderna, Inc.
- 22.16. New England Biolabs (NEB)
- 22.17. Oxford Nanopore Technologies
- 22.18. Pacific Biosciences (PacBio)
- 22.19. PerkinElmer
- 22.20. QIAGEN
- 22.21. Takara Bio
- 22.22. Thermo Fisher Scientific
- 22.23. Zymo Research
- 22.24. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF

PRICING DETAILS

Single-User Upto 2 Users - [PDF + Excel Only]

USD 4150

Multi-User Upto 10 Users - [PDF + Excel + PPT]

USD 5950

Enterprise-User Company-wide - [Report Pack + Benchmark + 6M Update]

USD 7750

Related Report

Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation